The potential of PIVKA-II as a treatment response biomarker in hepatocellular carcinoma: a prospective United Kingdom cohort study

Sagar, Vandana; Herring, Kathyrn; Curbishley, Stuart M.; Hodson, James; Fletcher, Peter; Karkhanis, Salil; Mehrzad, Homoyon; Punia, Pankaj; Shah, Tahir; Shetty, Shishir; Ting, Yuk

doi:10.18632/oncotarget.28136

Cited by 9 publications

(7 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1 b). A similar association with HCC size has previously been described for DCP and AFP-L3 but not AFP (Sagar et al 2021 ; Sauzay et al 2016 ). Our observations further support the relationship between the GALAD score and disease progression and/or tumor biology.…”

Section: Discussionsupporting

confidence: 83%

The GALAD score and the BALAD-2 score correlate with transarterial and systemic treatment response and survival in patients with hepatocellular carcinoma

Olbrich,

Niemeyer,

Seiffert

et al. 2024

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

Purpose The GALAD score and the BALAD-2 score are biomarker-based scoring systems used to detect hepatocellular carcinoma (HCC). Both incorporate levels of alpha-fetoprotein (AFP), lens culinaris agglutinin-reactive AFP (AFP-L3), and des-gamma-carboxy prothrombin (DCP). Our objective was to examine the relationship between the GALAD score as well as the BALAD-2 score and treatment response to transarterial or systemic treatments in patients with HCC. Methods A total of 220 patients with HCC treated with either transarterial (n = 121) or systemic treatments (n = 99; mainly Sorafenib) were retrospectively analyzed. The GALAD score and the BALAD-2 score were calculated based on AFP-L3, AFP, and DCP levels measured in serum samples collected before treatment. The results were correlated with 3-month treatment efficacy based on radiologic mRECIST criteria. Results The GALAD score showed a strong correlation with BCLC stage (p < 0.001) and total tumor diameter before treatment (p < 0.001).The GALAD score at baseline was significantly lower in patients with a 3-month response to transarterial (p > 0.001) than in refractory patients. Among patients receiving systemic treatment, the median BALAD-2 score at baseline showed a strong association with response at month 3 (p < 0.001). In the transarterial treatment group, the GALAD score (AUC = 0.715; p < 0.001) as well as the BALAD score (AUC = 0.696; p < 0.001) were associated with overall survival, hereby outperforming AFP, AFP-L3 and DCP. Conclusion The GALAD score as well as the BALAD-2 score hold significant promise as a prognostic tool for patients with early or intermediate-stage HCC who are undergoing transarterial or systemic treatments.

show abstract

Section: Discussionsupporting

confidence: 83%

The GALAD score and the BALAD-2 score correlate with transarterial and systemic treatment response and survival in patients with hepatocellular carcinoma

Olbrich,

Niemeyer,

Seiffert

et al. 2024

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

show abstract

“…PIVKA-II exhibits robust diagnostic performance, with a high sensitivity of 97.1% and specificity of 93.3%. These values suggest that PIVKA-II is highly effective in correctly (Sagar et al, 2021b). The assessment of PIVKA-II's efficacy in identifying AFPnegative HCC cases demonstrates its high sensitivity (97.14%) and specificity (93.30%) in this specific subgroup.…”

Section: Discussionmentioning

confidence: 87%

Role and Elevating Prognostic Precision of Pivka-Ii as a Superior Biomarker in HCC Diagnosis, Surpassing Afp

YASEEN,

ANWAR,

AHMAD

et al. 2024

Biol Clin Sci Res J

View full text Add to dashboard Cite

The objective of this study was to evaluate the diagnostic accuracy of PIVKA-II as compared to AFP for the detection of hepatocellular carcinoma (HCC) and its potential as a devoid prognostic biomarker. With genomic discoveries, including gene mutations, epigenetic alterations, and non-coding RNAs, the context around HCC biomarkers has increased. The relevance of prognostic and predictive biomarkers is growing as they support treatment choices and evaluate clinical outcomes. These indicators are significant tools in enhancing patient care because they improve diagnosis, direct therapy, forecast outcomes, and evaluate treatment responses. Comprehensive information on the predictive value of several markers, however, is still lacking. In this study, 85 people took part, including those older than 18 with hepatocellular carcinoma in a range of clinical stages. Three groups represented the study population, comprising 85 individuals in total: group 1 consisted solely of patients with HCC, group 2 included patients with benign liver disease, and group 3 was designated as the control group. A male predominance is found in groups, except group 2. The quantity of PIVKA-II in serum was measured using an automated analyzer that was based on the CMIA. The immunoassay method was applied to determine the concentration of AFP. The statistical analyses of PIVKA-II and AFP consisted of sensitivity 90–99% and 58–81%, specificity 68–99%, and 61–98% with a 95% CI, respectively. The findings emphasize PIVKA-II's superior performance as a biomarker of cancer response when compared to AFP.

show abstract

“…Therefore, the monitoring of PIVKA-II concentrations seems to be a reliable tool. Sagar and coworkers [ 21 ] advocated the monitoring of PIVKA-II and AFP levels in patients with hepatocellular cancer (HCC) treated with sorafenib. They showed that steady concentrations of PIVKA-II represented stable disease but gradual increase in concentrations was found in patients with the progression of the disease.…”

Section: Discussionmentioning

confidence: 99%

“…Patients with microvascular invasion and poorly differentiated cancer had significantly higher concentrations of PIVKA-II, a phenomenon which was not found in AFP concentrations. Similarly, advanced stages of HCC had significantly higher concentrations of PIVKA-II than early stages, and the increase in concentrations with advancing stages was higher than in AFP [ 21 ]. To summarize, firstly changes in RCV of only about 25% of previous value are a strong signal of probable harmful disease progression.…”

Section: Discussionmentioning

confidence: 99%

Biological variation of PIVKA-II in blood serum of healthy subjects measured by automated electrochemiluminescent assay

Jabor,

Kubíček,

Čásenská

et al. 2024

Practical Laboratory Medicine

View full text Add to dashboard Cite

The potential of PIVKA-II as a treatment response biomarker in hepatocellular carcinoma: a prospective United Kingdom cohort study

Cited by 9 publications

References 40 publications

The GALAD score and the BALAD-2 score correlate with transarterial and systemic treatment response and survival in patients with hepatocellular carcinoma

The GALAD score and the BALAD-2 score correlate with transarterial and systemic treatment response and survival in patients with hepatocellular carcinoma

Role and Elevating Prognostic Precision of Pivka-Ii as a Superior Biomarker in HCC Diagnosis, Surpassing Afp

Biological variation of PIVKA-II in blood serum of healthy subjects measured by automated electrochemiluminescent assay

Contact Info

Product

Resources

About